https://doi.org/10.30702/Ophthalmology.2019/10.137686

Veselovska Z. F., Veselovska N. M., Zaporozhchenko I. B.

Kyiv Medical University, Eye Clinic of Kyiv City Hospital No 1, Kyiv, Ukraine

Abstract

The aim of research is to study the hypotensive, neuroprotective effects and side effects of Monoprost in comparison with the original preserved latanoprost (Xalatan).

Material and methods. The I group includes 20 patients (26 eyes), who obtained instillations of preserved latanoprost (one dose before night). The II group consists of 20 patients (26 eyes), who used eye drops of Monoprost (one dose before night).

The observation period was 12 weeks. The examination included visual acuity, perimetry, tonometry and optical coherence tomography of the retina and optic nerve.

Results. The examination revealed high hypotensive effect of Monoprost in comparison of the original preserved latanoprost (IOP reduction at the end of the study was 32% and 29%, respectively). Eye drops of Monoprost was characterized by a low level of local side effects, leading to a decrease IOP in patients with POAG by an average of 32% from the initial level. The achieved hypotensive effect and the absence of the toxic effect of preservatives provided the effect of indirect neuroprotection and was accompanied by positive dynamics of both visual acuity and perimetry and OCT data.

The drug is characterized by low level of side effects and may be recommended as a hypotensive drug in patients with primary open-angle glaucoma.

Keywords: primary open-angle glaucoma, Monoprost, Xalatan, intraocular pressure, neuroprotection.

REFERENCES

1. European Glaucoma Society. Terminology and Guidelines for Glaucoma. 4th Edition. 2018. 196 p.
2. Bezditko PA. [Neuroprotective therapy for open-angle glaucoma: expert opinion]. Zdorovia Ukrainy. 2018 July;13–14(434–435):35–6. Russian.
3. Drozhzhina GI, Grupcheva K, Muzhichuk EP. [Monoprost – Innovations in Glaucoma Therapy]. Zdorovia Ukrainy. 2018 July;13–14(434–435):50–1. Russian
4. Dry eye diseases 2017 TFOS DESII Report of the International Dry Eye Workshop.
5. EMEA Public Statement on Antimicrobial Preservatives in Ophthalmic Preparations for Human Use. EMEA/622721/2009, London, 08 December 2009.
6. Khawaja Ap, Crabb DP, Jansonius NM. The role of ocular perfusion pressure in glaucoma cannot be studied with multivariable regression analysis applied to surrogates. Invest Ophthalmol Vis Sci. 2013;54(7):4619–20.
7. Report of the Management and Therapy Subcommittee of the International Dry Eye Workshop (2017).
8. Sena DF, Lindsley K. Neuroprotection for treatment of glaucoma in adult. The Cochrane database of systematic reviews. 2013;2:CD006539.
9. Boland MV, Ervin AM, Friedman DS, et al. Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force. Ann Inrern Med. 2013;158(4):271–9.
10. Thygesen J. Glaucoma therapy: preservative-free for all? Clinical Ophthalmology. 2018; 12:707–17.
11. Peters D, Bengtsson B, Heijl A. Factors associated with lifetime risk of open-angle glaucoma blindness. Acta Ophthalmol. 2014;92(5):421–5.
12. Rouland JF, Traverso CE, Stalmans I, Fekih LE, Delval L, Renault D, Baudouin C. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. Br J Ophthalmol. 2013 Feb; 97(2):196–200.
13. Cucherat M, Rouland JF. Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension. An adjusted indirect comparison meta-analysis. Acta Ophtalmologica. 2012;90(s249).
14. Cucherat M, Stalmans I, Rouland JF. Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted Indirect comparison meta-analysis of randomized clinical trials. J Glaucoma. 2014 Jan;23(1):e69–75.
15. Economou MA, Laukeland H, Grabska-Liberek I, Rouland JF. Long-term efficacy and safety of preserved and preservative-free prostaglandins eyedrops. Final results of the FREE Survey. WGC 2017.
16. Martinez-de-la-Casa JM, Perez-Bartolome F, Urcelay E, et al. Tear cytokine profile of glaucoma patients treated with preservative-free or preserved latanoprost. Ocul Surf. 2017; 15(4):723–9.
17. Van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005;112(7):1177–85.
18. Arias A, Schargel K, Ussa F, Canut MI, Robles AY, Sánchez BM. Patient persistence with first-line antiglaucomatous monotherapy. Clin Ophthalmol. 2010;4:261–7.
19. Newman-Casey PA, Blachley T, Lee PP, Heisler M, Farris KB, Stein JD. Patterns of Glaucoma Medication Adherence over Four Years of Follow-Up. Ophthalmology. 2015; 122(10):2010–21.
20. Lemij HG, Hoevenaars JG, van der Windt C, Baudouin C. Patient satisfaction with glaucoma therapy: reality or myth? Clin Ophthalmol. 2015;9:785–93.
21. Aptel F, Choudhry R, Stalmans I. Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension. Curr Med Res Opin. 2016; 32(8):1457–63.
22. Zheng Y Wong TY Mitchell P Distribution of ocular perfusion pressure and its relationship with open-angle glaucoma: the Singapore Malay Eye Study. Invest Ophthalmol Vis Sci. 2010;51:3399–404.
23. Ramdas WD, Wolfs RC, Hofman A, et al. Ocular perfusion pressure and the incidence of glaucoma: real effect or artifact? The Rotterdam Study. Invest Ophthalmol Vis Sci. 2011; 52: 6875–81.

Received: 11 Oct. 2019

Published: December 2019